The article you requested is
ASCP Corner: Why Aren't MAOIs Used More Often?
J Clin Psychiatry 2009;70(1):139-140
Copyright 2009 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
Purchase this PDF for $30
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($125) or print + online ($161 individual).
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email
While I have spent most of my last 45 years in psychiatry
working in an academic setting and doing clinical research, I
have always had an active practice focused on major affective
disorders, especially treatment-resistant or treatment-refractory
cases. It is my impression that monoamine oxidase inhibitors
(MAOIs) are currently underutilized in the clinical practice of
psychiatry. Very few of the treatment-resistant patients that I
see have received a serious trial of MAOI therapy.